Tretinoin ( DrugBank: Tretinoin )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
| 62 | Paroxysmal nocturnal hemoglobinuria | 1 |
| 75 | Cushing disease | 2 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00919555 (ClinicalTrials.gov) | June 2008 | 8/6/2009 | Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) | Phase IIA Trial: Tretinoin and Pioglitazone HCL Combination Therapy in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Pioglitazone and Tretinoin;Drug: Tretinoin and Pioglitazone HCL;Drug: Placebo | Phoenix Neurological Associates, LTD | NULL | Completed | 18 Years | 85 Years | Both | 28 | Phase 1/Phase 2 | United States |
62. Paroxysmal nocturnal hemoglobinuria
Clinical trials : 292 / Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000039675 | 2021-01-01 | 2020-11-05 | Phase II clinical trial of the superiority of all-trans retinoic acid in the treament of paroxysmal nocturnal hemoglobinuria | Phase II clinical trial of the superiority of all-trans retinoic acid in the treament of paroxysmal nocturnal hemoglobinuria | paroxysmal nocturnal hemoglobinuria | experimental group:Tretinoin 0.33mg/kg.d; methylprednisolone 0.8mg/kg.d;Control test:methylprednisolone 0.8mg/kg.d; | Department of Hematology, Second Medical Center, Chinese PLA General Hospital | NULL | Recruiting | 14 | 80 | Both | experimental group:10;Control test:10; | Phase 2 | Chinese |
75. Cushing disease
Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004019-29-IT (EUCTR) | 15/07/2021 | 07/10/2020 | Italian study to evaluate the efficacy of retinoic acid and cabergoline therapy in combination in Cushing's disease. | Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study. - CRACCA | Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where it is contraindicated or refused by patient. MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Dostinex Product Name: Cabergolina Product Code: [G02CB03] INN or Proposed INN: CABERGOLINA Other descriptive name: NON COMMERCIAL Trade Name: VESANOID Product Name: Tretinoina Product Code: [L01XX14] INN or Proposed INN: TRETINOINA Other descriptive name: NON COMMERCIAL | Dipartimento di Medicina-DIMED, università di Padova | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | Italy | ||
| 2 | EUCTR2008-006379-65-IT (EUCTR) | 27/10/2008 | 12/11/2008 | Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Retinoic acid in Cushing`s disease | Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Retinoic acid in Cushing`s disease | sperimentation only in patients | INN or Proposed INN: Tretinoin | ISTITUTO AUXOLOGICO ITALIANO | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy |